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Objective: The aim of this study was to evaluate the efficacy of a new gelatin-sealed graft prebonded with two antibiotics
in resisting infection with Staphylococcus aureus (S aureus) A980142 after direct bacterial application in a dog model.
Methods: Twelve 6.0-mm polyester grafts were implanted in dogs end-to-end into the infrarenal aorta. The dogs were
divided into two groups. A test group (n  6) received experimental antibiotic-bonded gelatin-sealed knitted polyester
grafts, loaded with two antibiotics, rifampin and tobramycin. A control group (n 6) received commercial gelatin-sealed
knitted polyester grafts. At the end of graft implantation, 50 l of a 1.8 104 CFU/mL S aureus solution were instilled
directly over the graft. One week after implantation, grafts were harvested with sterile technique. Quantitative cultures
were obtained from all the harvested grafts. The results were expressed as colony-forming units per cm2 of surface of the
graft. Bacteriological study was also performed on various tissue samples. The 2 test was used to compare the culture
proven infection of control and antibiotics-bonded grafts.
Results: Mean inoculum size was similar in the two groups of dogs. Five of the six control grafts grew S aureus A980142
at the time of graft removal, whereas none of the six antibiotic-bonded gelatin-sealed grafts were infected (P  .0192).
None of the organ samples were infected in the group implanted with antibiotic-bonded grafts, whereas 15/34 samples
grew S. aureus in the control group.
Conclusion: These results indicate that this gelatin sealed graft prebonded with two antibiotics resists infection caused by
S aureus graft contamination in a dog model. ( J Vasc Surg 2007;46:1026-31.)
Clinical relevance. Graft infection remains a crucial problem in vascular surgery, even if its occurrence is rare. Several
authors have proposed the use of antibiotic-bonded grafts to prevent or to treat graft infections. Development of grafts
that are resistant to infection has considerable appeal, but, until now, none is commercially available. We used a dog
model to evaluate the resistance to infection of a new gelatin-sealed graft manufactured prebonded with two antibiotics,
rifampin and tobramycin. In this study, we demonstrate that this prebonded graft resists to infection caused by local
contamination with Staphylococcus aureus. Further studies are required to confirm our experimental findings.Infection of an aortic graft is one of the most feared
complications in vascular surgery. Fortunately, infection of
an aortic prosthesis is a relatively rare occurrence.1 The
treatment of an infected aortic prosthesis continues to
challenge the vascular surgeon. Conventional manage-
ment of aortic graft infection consists of extraanatomic
bypass, complete removal of the infected graft, ligation
of the infrarenal aorta, and debridement of peripros-
thetic tissue.2,3 However, conventional treatment is as-
sociated with secondary complications in more than 25%
of cases.4 In situ reconstruction presents a number of
theoretical advantages.5-7 Its main limitation is the risk
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1026of reinfection of the new graft in an infected surgical field
or by hematogenous seeding.
Development of an infection-resistant artificial graft has
considerable appeal to prevent and/or treat aortic graft
infection. Review of the literature shows several experimen-
tal approaches, including the bonding of antibiotics, silver
or both to vascular grafts,8-25 the inhibition of bacterial-cell
communication by use of a quorum-sensing inhibitor,26 or
an exogenous sustained-release vancomycin sheet placed
on the graft.27
Several bonding agents were used to attach various
antibiotics or antimicrobials to vascular grafts. In particular,
gelatin used as a sealant for polyester grafts allows the
bonding of antibiotics to the sealant.28 Using that ap-
proach and a simple soaking technique in previous experi-
mental studies, we showed the efficacy of rifampin-bonded
gelatin-sealed grafts in the prevention of S aureus bactere-
mic graft infection.29 We also demonstrated that such
rifampin soaked gelatin-sealed grafts were effective to treat
aortic graft infections due to Staphylococcus epidermidis
with in situ replacement,30 even when the bacterial strain
was resistant to rifampin.31
Rifampin is very effective against Gram-positive organ-
isms, while silver grafts have a better in vitro activity against
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rial spectrum of activity of antibiotic bonded vascular grafts,
to cover both Gram-positive and Gram-negative bacteria, a
new vascular has been developed, which is manufactured
prebonded with two antibiotics, rifampin and tobramycin.
Tobramycin was chosen because of its good activity against
Gram-negative bacteria. In a previous experimental work,
we studied healing, toxicity, and elution rates of this new
vascular graft. This study32 showed that the healing of this
prebonded graft was similar to that of commercial gelatin-
sealed grafts, without any signs of toxicity.
The aim of this study was to test the efficiency of this
gelatin-sealed graft, prebonded with two antibiotics during
manufacturing, in resisting infection after direct bacterial
application in a dog model.
MATERIAL AND METHODS
Protocol
The infrarenal aorta of 12 dogs was replaced using
knitted polyester vascular grafts. In six dogs, the aorta was
replaced with a conventional gelatin-sealed graft (control
group). In the other six dogs, we used gelatin-sealed grafts
bonded with two antibiotics, rifampin and tobramycin,
duringmanufacturing. On each operative session, two dogs
were operated consecutively, one receiving a control graft,
and one receiving a test graft. However, due to the yellow
color of the test grafts, operators could not be blinded. All
dogs were scheduled to be sacrificed 7 days after the first
procedure.
Grafts
Two types of grafts were used: (1) commercial gelatin-
sealed knitted polyester grafts (Gelsoft Plus, Vascutek
Terumo, Inchinnan, Scotland) used as controls (control
group); (2) experimental antibiotic-bonded gelatin-sealed
knitted polyester grafts, also manufactured by Vascutek
Terumo, loaded with two antibiotics: rifampin and tobra-
mycin. All grafts were 6-mm diameter tubes. The manufac-
turing process for the antibiotic loaded grafts is substan-
tially the same as the normal gelatin-sealed version. The
antibiotics are incorporated into the gelatine sealant during
manufacturing. The gelatin impregnation process is de-
scribed in US patent 4,747,848. Briefly, a partially succiny-
lated mixture of USP ossein gelatin is dissolved in water at
a concentration of 10%. After filtration, this solution is used
to vacuum impregnate the polyester substrate. The solu-
tion forms a gel, which is cross-linked with 20% aqueous
formaldehyde. The excess fixative is removed by multiple
rinsing in purified water, followed by plasticization with
glycerol. At this stage in the process, an extra step is added
for incorporation of the antibiotics. The grafts are im-
mersed in a solution of 13 g/L of rifampin and 1.7 g/L of
tobramycin in a mixture of propanol, water, and glycerol.
After drying, the grafts are sterilized in the normal, low-
temperature, 100% ethylene oxide cycle at a temperature of
37oC. This regime gives a loading of 1.22 mg of rifampin
and 0.282 mg tobramycin per centimeter of the 6 mmgrafts used in the animal model. This level was chosen to
ensure that the largest clinically used graft would contain
less than the normal daily dose of each drug.
Both the gelatin and the antibiotics are unaffected by
this process. The gelatin retains its rapid resorption time of
2 weeks. In-vitro evaluations have shown that the grafts
retain a high bactericidal level of activity for 3 days, with
most of the drug removed by 7 days. These levels were
designed to ensure that the largest graft used clinically
would contain less than the normal daily dose of both
drugs.
Bacterial strain
The bacterial strain used in this study was Staphylococcus
aureus (S aureus) A980142, from the French National
Reference Center. This strain is susceptible to rifampin but
resistant to methicillin (heterogeneous type) and tobramy-
cin. Bacteria were stored at 80oC using cryobeads.
Bacterial challenge preparation
Challenge inoculums were prepared as follow: strain
A980142 was cultured on sheep blood agar for 18 hours at
37oC. Colonies were picked up and emulsified in sterile
normal saline to obtain a turbidity of 0.5 MacFarland
(Densimat apparatus, Biomérieux, Marcy l’Etoile, France).
The suspension (5107 colony forming units (CFU)/
mL) was diluted appropriately in sterile normal saline to
obtain the required bacterial concentration. Local graft
contamination was established by topical delivery of a 50 l
volume of challenge inoculum with a sterile pipette tip.
Bacterial concentration of the challenge inoculum was
checked by the viable plate count method.
Surgical protocol
Twelve Anglo-French mongrel dogs (nine female and
three male), weighting 13 to 18 kg were used. Animals
were admitted to the laboratory 5 days priors to surgery to
allow acclimatization to food and environment.
Aortic replacement. After anesthetization by intrave-
nous injection of sodium thiopental (10 mg/kg), dogs
were intubated and mechanically ventilated with 100%
oxygen. Anesthesia was maintained with isoflurane 1% to
2% end-tidal concentration. Hydration was maintained
with continuous infusion of Ringer’s lactate at the rate of
15 ml/kg/h. The dogs were then placed in a semilateral
right decubitus position, with the left side up. Body tem-
perature was maintained near 37.5oC by forced-air warm-
ing. The abdomen was shaved and skin was prepped with
10% povidone-iodine solution. A transperitoneal left lateral
laparotomy was performed under sterile surgical condi-
tions. The infrarenal aorta was exposed from left renal
artery to aortic trifurcation. Lumbar and inferior mesen-
teric arteries were ligated (Vicryl, Ethicon, Johnson &
Johnson Intl, Brussels, Belgium) and transected to allow
aortic resection. After intravenous administration of a 0.5
mg/kg bolus of heparin, the aorta was clamped just below
the renal arteries and at its end. A short aortic segment
(8- to 10-mm) was resected. The cut ends of the aorta were
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sectioned aorta. The prosthesis was implanted with two
end-to-end anastomoses. Each anastomosis was performed
end-to-end, with hemicircumferential running 6/0-13
polypropylene sutures (Prolene Ethicon, Johnson& Johnson
Intl, Brussels, Belgium). Hemostasis was then checked.
Graft contamination. Fifty l of bacterial solution
were instilled directly over the graft. The graft was not
sponged dry after this local contamination. The graft was
covered by direct closure of the posterior parietal perito-
neum. Abdominal wall was closed in layers with a standard
surgical technique. Mechanical ventilation was maintained
until awakening. Dogs did not receive postoperative anti-
biotic prophylaxis or blood transfusion. Ketoprofene and
morphine were administered for postoperative analgesia.
Dogs were placed in individual cages and examined daily
and monitored for any symptoms of systemic toxicity,
which could have been caused by the graft or the
antibiotics.
This study was approved by the Animal Care and Ethics
Committee at Montsouris Mutualist Institute (Paris,
France). All dog care complied with the “Principles of
Laboratory Animal care” and the “Guide for the care and
use of Laboratory Animals” (National Institute of Health
Publication no80-23, revised 1985).
Explantation of grafts
General anesthesia was administered as previously de-
scribed. Before sacrifice, a venous blood sample was col-
lected for blood culture and white blood cell (WBC) count.
Sacrifice was performed under sterile surgical conditions.
An intravenous bolus of 1mg/kg heparin was administered
immediately after anesthesia. Exsanguination was percuta-
neously performed in each dog. A midline laparotomy was
used to perform harvesting, in order to avoid contamina-
tion from the first procedure. Any macroscopic signs of
prosthetic and general infection were noted. First, speci-
mens for bacteriological studies were collected using sterile
technique from various organs (liver, spleen, lung, left
kidney). Secondly, the graft was harvested taking care to
maintain sterility. Remaining blood was gently expressed
from the graft. Grafts and pieces of organs for bacteriolog-
ical studies were put in separate sterile containers.
Bacteriological studies
After being weighed, graft and tissue specimens were
aseptically treated in a bead-beater (Mixer Mill MM301
Retsch GmbH, Haan, Germany) with 1 mm glass beads
and 30 mL normal saline, for 5 minutes, at 30 oscillations/
sec frequency. The number of viable bacteria in this sample
was determined by plating serial fivefold dilutions on Muller-
Hinton agar plates and by counting CFU after 48-hour
incubation at 37oC. Results were expressed as the number
of CFU per cm2 of surface of the graft (minimal detection
limit, 30 CFU per sample) or per gram of tissue specimen
(minimal detection limit, 3.102 CFU per sample). A more
sensitive qualitative method was also used to check the
sterility of samples (minimal detection limit, 30 CFU persample). A 13 mL volume of Schaedler broth was inocu-
lated with 1 mL of each suspension. Aliquots were subcul-
tured on sheep blood agar on day 2, and between day 2 and
day 7 if turbid. The samples were considered positive if S
aureus A980142 was recovered from any subcultures.
Statistical analysis
The number of positive culture infected grafts observed
in the two groups of dogs was compared with the 2 test.
Statistical significance was assigned when P values were less
than .05.
RESULTS
The mean inoculum size was 1.83  104 CFU/mL
(range 1 104 to 2 104 CFU/mL) in the test group and
1.82  104 (range 6  103 to 4  104 CFU/mL) in the
control group, without significant differences between the
two groups of dogs. All dogs were alive at the time of
sacrifice. Five of the six control grafts grew S aureus
A980142 at the time of graft removal, whereas none of the
six antibiotic bonded grafts were infected. The mean bac-
terial count of infected grafts was 2  103 CFU/cm2
(range 3 102 to 1010). Results of bacteriological cultures
of the grafts and tissue specimens are shown in the Table.
Control group. All dogs except one were sacrificed
and grafts harvested at the scheduled date, day 7. A control
dog was sacrificed and graft harvested at day 6 because it
was lethargic, refusing food and water, with persistent
diarrhoea since day 2 post implantation. At the time of
harvesting, we noticed two dogs with periprosthetic hema-
toma, two dogs with suspicious periprosthetic collection,
and, in the dog sacrificed at day 6, an intraperitoneal
hemorrhage due to a proximal pseudo-aortic aneurysm. In
this last dog, aWBC elevation was found (41.8 109 white
cells/l). All six grafts except one remained patent at the
time of harvesting. Mean WBC of control dogs was 19.3
109 white cells/l (range 11  109 to 41.8  109 white
cells/l). Blood cultures were positive for S aureusA980142
in three dogs. Five of the six control grafts were infected
with S aureus A980142. Fifteen of the 34 bacteriological
cultures of tissues specimens were positive and seven other
specimens were positive after enrichment of the medium.
Test group. All dogs were sacrificed and grafts har-
vested at the scheduled date, day 7. All dogs appeared
healthy. At the time of harvesting, we noticed a peripros-
thetic hematoma in two dogs and periaortic lymphadenop-
Table. Bacteriologic study of organ samples
No. with positive culture/total number examined
Periprosthetic
tissues Kidney Spleen Liver Lung Others
Control dogs 5/6* 3/6* 1/6* 2/6* 1/6* 3/4
Test dogs 0/6 0/6 0/6 0/6 0/6 0/2
*Without enrichment of medium.athies in two others. There were no pseudo-aortic aneu-
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MeanWBCof test dogs was 10.2 109/l (range 4.5 109
to 14.2  109 white cells/l). Blood cultures at the time of
graft harvesting were negative in all test dogs. None of the
antibiotic bonded grafts grew S aureus A980142. This
difference was statistically significant (P value  .0192)
compared with the control group. Bacteriological cultures
of tissues specimens were constantly negative in test dogs.
DISCUSSION
This experimental study confirms the efficacy of gela-
tin-sealed grafts manufactured prebonded with rifampin
and tobramycin to resist infection from S aureus in the dog.
We used a dog model because prior studies have clearly
demonstrated the reproducibility and the clinical signifi-
cance of the canine model to study graft infections due to
bacteremia or local contamination and preventive or ther-
apeutic strategies.24,29-31 The Anglo-French dogs used
in these experiments where not purpose-bred pathogen-
controlled animals, as suggested by Schmacht et al24 in an
attempt to eliminate uncontrolled variables. However,
quantitative culture results within the two groups of ani-
mals were fairly consistent, as observed in our previous
works.29-31
A criticism of this work may be the absence of several
other control groups, such as unbonded grafts with or
without gelatin sealing, unsealed grafts soaked in rifampin
or tobramycin, gelatin-sealed grafts soaked in rifampin or
tobramycin, and gelatin-sealed grafts soaked in rifampin
and tobramycin. However, we felt that these groups were
not required for several reasons. First, the primary focus of
the study was resistance to infection of the manufactured
grafts prebonded with antibiotics. Second, we previously
demonstrated (1) the inability of unsealed polyester grafts
to bind significant amounts of rifampin,33 and (2) the
constant contamination of unbonded gelatin-sealed grafts
and the resistance of rifampin bonded gelatin-sealed grafts
when submitted to a bacteremic challenge or a local con-
tamination in the dog.29-31 Based on these previous results,
and for ethical reasons, we decided to focus on the com-
parison of the prebonded graft with the unbonded gelatin-
sealed graft.
Development of infection resistant vascular grafts has
considerable appeal. However, when designing antibiotic
loaded grafts, several considerations are important. Pre-
bonding is not only a matter of convenience over point of
use loading, it also ensures a consistent standardized dose.
Activity should be high at implant and perioperatively, but
the antibiotics should not persist for longer than a few days,
to minimize the risk of resistance. It is essential that the
process, including sterilization, should not change the
chemical nature of either the drugs or the substrate used as
a carrier. Untoward reactions could affect the resorption of
the sealant and impair healing.
Grafts containing silver and collagen are available in
Europe.34 However, with the use of an animal model, we
demonstrated in 2002 that a silver collagen coated graft is
less resistant to bacteremic infection with S aureus thanrifampin gelatin-sealed grafts.35 Using a dogmodel and a 2
107 local inoculum, Schmacht et al demonstrated that
rifampin-soaked grafts exhibited a higher initial resistance
to local contamination with S aureus than silver/collagen-
coated grafts, but with a secondary growth curve.24 An-
other polyester graft coated with elemental silver with or
without gelatin impregnation has been evaluated in vitro
with a significant antibacterial effect, but without animal
evaluation until now.25 The efficacy of a sustained-release
system made of a poly-L-lactide-co-caprolactone and
vancomycin sheet has also been evaluated in a murine
subcutaneous pouch model, with a reduction, but not an
eradication of prosthetic infection.27 The possibility of
preventing bacterial colonization and infection by coating
grafts with the quorum-sensing inhibitor RNAIII inhibit-
ing peptide (RIP) has also been evaluated by Dell’Acqua
et al.26 Using a rat model of subcutaneous pouch in which
they implanted collagen-sealed polyester grafts with or
without local and with or without intraperitoneal adminis-
tration of RIP, these authors showed that RIP inhibited
S aureus or S epidermidis graft infection when applied
locally and systemically. However, no more data are avail-
able regarding the coating of vascular grafts with RIP to
prevent clinical vascular graft infection.
Antibiotic bonding has been extensively investigated
with different antimicrobial agents and different techniques
of bonding. However, as yet, no manufactured graft has
been made commercially available prebonded with antibi-
otic(s). One of the greatest advantages of grafts prebonded
with antibiotic(s) would be their availability in any circum-
stances, especially in emergency, or in patients at high risk
of infection. Three prerequisites have to be fulfilled to
ensure the efficacy of antibiotic bonded graft: (1) antibiot-
ics used should be effective against bacteria commonly
observed in vascular graft infections, (2) the concentration
of antibiotic(s) should be sufficient to ensure an appropri-
ate local bactericidal action for a period of time long
enough to protect the graft, without general toxicity and
allergenic reaction, and (3) antibiotic release should not
compromise the healing of the graft, while still ensuring
prolonged perioperative bactericidal activity.
In this new antibiotic bonded graft, rifampin was chosen
because of itswell-knownactivity againstGram-positive cocci,
with remarkable antistaphylococcal potency. Moreover,
rifampin has a high affinity for the gelatin sealant. This
affinity is thought to be due to ionic bonding.28 The action
of rifampin has been known since 1967 and is effective
because of its direct action on bacterial RNA synthesis.36
The addition of tobramycin enlarges the antibiotic spec-
trum, with activity against Gram-negative strains. More-
over, this association should contribute in preventing the
emergence of rifampin resistance.37,38
Tobramycin-glue has already been studied by Shenk in
1989.11 In this study, none of the dogs with PTFE grafts,
treated with antibiotic glue, developed graft infection. The
authors concluded that glue with tobramycin was effective
in preventing and treating infection.
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study was 13 mg/mL. This was lower than the amount
used in previous studies.35 However, we have previously
showed the efficacy in preventing vascular graft infection of
a gelatin-sealed graft soaked in a solution containing
rifampin at 1 mg/mL.29 Koshiko39 implanted rifampin-
gelatin grafts (after soaking the graft in a rifampin solution
with 1 mg/mL of rifampin) in dogs. He failed to demon-
strate the efficacy of these grafts in case of virulent organ-
isms like S aureus. However, in this study, the organism
concentration (1  108 organism/mL) was higher than
our previous study. One of the advantages of using local
delivery of antibiotics is to have a slow and continuous
antibiotic release from the graft. Different bonding tech-
niques have been used. Some authors have reported using a
glue to allow antibiotic release over a period of 1 to 2
months.12 However, glue has some drawbacks (toxic to
tissues, absence of resorption by the body). Covering the
first postoperative period appears to be sufficient to prevent
early graft infection. We have previously shown in a dog
healing model that significant amounts of rifampin and
tobramycin were detectable until day 14 and 7 post graft
implantation, respectively.32 This suggests that the pro-
gressive disappearance of rifampin is probably the result of
the resorption of the gelatin sealant, and that drugs are not
affected by the manufacturing process. This should allow
protection during the immediate perioperative stage which
represents the maximum risk for vascular infections.
In conclusion, these results indicate that this gelatin-
sealed graft manufactured prebonded with antibiotic resists
infection caused by S aureus graft contamination in a dog
model. Further clinical studies are required to confirm
these experimental findings.
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